Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer

NCT02069145 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Cancer
Liver Cancer

Interventions

DRUG: OMP-54F28 with Sorafenib

Sponsor

OncoMed Pharmaceuticals, Inc.